Experience With Lurbinectedin in SCLC

The conversation highlights clinical observations from the use of recently approved second-line therapies. Panelists note consistent response rates in appropriate patients, particularly those with sensitive relapse. Common adverse events include fatigue, myelosuppression, and gastrointestinal symptoms, which are manageable with supportive care.

Patient selection is emphasized as critical for maximizing benefit. Those with adequate marrow function, controlled symptoms, and no significant hepatic impairment tend to tolerate therapy better. The segment underscores that managing expectations and providing close monitoring are essential to achieving optimal results.

Overall, these agents provide meaningful options in a historically difficult-to-treat population, although their integration into practice continues to evolve as new data emerge.